Biogen Expects 50% Royalty Cut After Ocrevus Biosimilars Enter Market
As Trial With Zydus Over Generic Vumerity Is Set For July 2025
As ocrelizumab biosimilar entry is coming closer, Biogen hopes that development partner Genentech will protect the franchise with new Ocrevus products.
